Tobramycin and ambroxol aerosol inhalation solution and preparation method thereof
Tobramycin and ambromycin free of sodium bisulfite were prepared by mixing ambromycin hydrochloride with a latent solvent at room temperature and combining with tobramycin solution, using specific thickeners and pH adjusters. Atomization inhalation solution solves the problems of reduced efficacy and low drug compliance, and improves product stability and safety.
Patent Information
- Application Number
- CN202411042987.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-26
- Publication Date
- 2024-11-15
AI Technical Summary
In the prior art, tobramycin and ambroxol atomized inhalation solution cannot be used effectively, resulting in a decrease in drug efficacy and low drug compliance for patients. The use of the antioxidant sodium bisulfite will cause irritating side effects on the respiratory tract. There are safety hazards.
Tobramide free of sodium bisulfite is prepared by mixing ambroxol hydrochloride with a latent solvent at room temperature to shorten the dissolution time and mixing with tobramycin solution using specific thickening agents and pH regulators. Atomizing and ambroxol inhalation solution to ensure product stability and safety.
Improve the chemical stability and atomization performance of tobramycin and ambroxol solutions, avoid the irritating side effects of sodium bisulfite, enhance the patient's medication compliance, and maintain the quality of the preparation under accelerated conditions. sex.
Smart Images

Figure BDA0004972831560000051 
Figure BDA0004972831560000081 
Figure BDA0004972831560000091
Abstract
Description
Technical Field
[0001] The invention belongs to the field of pharmaceutical preparations, and in particular relates to a tobramycin and ambroxol atomized inhalation solution and a preparation method thereof. Background Art
[0002] Bronchiectasis (abbreviated as bronchiectasis) is a disease in which recurrent suppurative infections caused by various etiologies lead to repeated damage and / or obstruction of small and medium-sized bronchi, resulting in destruction of the bronchial wall structure, causing abnormal and persistent dilation of the bronchi. Usually, domestic patients with bronchiectasis are often accompanied by Pseudomonas aeruginosa (PA) infection, which has a significant impact on the progression and prognosis of bronchiectasis, can lead to repeated infections and prolonged illness, and poses a huge challenge to clinical treatment. Patients in the acute phase of bronchiectasis combined with PA infection will experience worsening cough, wheezing, dyspnea, general discomfort, increased sputum volume or changes in viscosity, or increased sputum purulent, which seriously affects their quality of life.
[0003] Tobramycin inhalation solution is the first inhaled antibiotic approved for marketing in my country. On the one hand, compared with other drugs used for PA clearance in bronchiectasis, tobramycin has a clear drug delivery target and few systemic adverse drug reactions, and its therapeutic status is gradually rising. On the other hand, while inhaled drug delivery increases the local effective drug concentration in the lungs, it avoids the high drug exposure in the body during traditional systemic delivery, which is prone to ototoxicity and nephrotoxicity, and also significantly reduces the risk of bacterial resistance. It is suitable for long-term maintenance of antibacterial treatment in patients with bronchiectasis. In addition, for chronic infections in patients with bronchiectasis, the British Thoracic Society, the European Respiratory Society and my country's drug use guidelines all recommend inhaled tobramycin or polymyxin for treatment. However, more than 70% of patients with bronchiectasis cough up a lot of sputum every day, which can cause secondary bacterial infections, leading to decreased lung function and continued destruction of immune defenses. Therefore, expectorant therapy is also very important in the treatment of bronchiectasis. The "Expert Consensus on Treatment and Diagnosis of Bronchiectasis in Adults in China" recommends that patients with bronchiectasis who have difficulty expectorating, poor quality of life, and poor postural drainage should try long-term use (>3 months) of an expectorant. Currently, two expectorants, ambroxol and acetylcysteine, are mainly used for bronchiectasis combined with PA infection. Ambroxol, as a mucolytic, can increase the secretion of serous glands and regulate the secretion of tracheal glands to reduce sputum viscosity, reduce mucin production, promote bronchial epithelial repair, and improve the turnover motility of the ciliated epithelial mucus layer. It is a commonly used expectorant.
[0004] Combined with the pathogenesis and symptoms of bronchiectasis combined with PA infection, antibacterial and expectorant treatment is required, and the combined use of tobramycin and ambroxol has a synergistic effect. Clinical trials have confirmed that it can significantly improve the treatment efficiency of patients, improve lung function and reduce the number of acute symptom exacerbations. Since the instructions for inhalation of ambroxol hydrochloride solution point out that "if it is necessary to mix and nebulize with other drugs, the pH value of the mixed solution should be avoided above 6.3 to prevent the increase in pH value from causing the free ambroxol to become ineffective or the solution to become turbid", and the pH value of tobramycin inhalation solution is 5.5-6.5, directly mixing ambroxol hydrochloride solution and tobramycin inhalation solution will affect the efficacy of the drug, and the method of taking the drug in succession will also double the patient's nebulization time and reduce the compliance of patients taking the drug for a long time. In addition, compared with the compound nebulized inhalation administration method, the oral ambroxol and nebulized inhaled tobramycin administration still used in clinical practice are also extremely inconvenient, and the patient's compliance with the medication is low.
[0005] At present, there are few studies on solving the problem that tobramycin inhalation solution and ambroxol inhalation solution cannot be used in combination. CN115531400A discloses a compound preparation of tobramycin and ambroxol and a preparation method thereof, which avoids the generation of the ambroxol impurity B by adding an antioxidant sodium bisulfite. However, sodium bisulfite is irritating to the respiratory mucosa, which is not only not conducive to the treatment of patients with bronchiectasis, but also may cause laryngeal and bronchial spasm asthma, wheezing, chest tightness, dyspnea, urticaria, anaphylactic shock, loss of consciousness and even death and other clinical adverse symptoms. Vomiting and diarrhea symptoms are also reported from time to time. In particular, the incidence of side effects of sodium bisulfite is higher when inhaled or intravenously administered than other routes of administration. In addition, foreign studies have also shown that patients with respiratory symptoms such as asthma are 3% to 10% sensitive to sulfites. The U.S. Food and Drug Administration (FDA) had clear regulations on the use of sulfites in pharmaceutical excipients in the 1980s: "Sulfites may cause allergic reactions in certain susceptible groups, especially those with asthma. Any prescription drug, no matter how much sulfite is added, should be accompanied by a warning statement."
[0006] Therefore, how to prepare a compound tobramycin and ambroxol nebulized inhalation solution with good drug stability and low irritation without using the antioxidant sodium bisulfite is an urgent problem to be solved. Summary of the invention
[0007] In order to overcome the shortcomings of the prior art using the antioxidant sodium bisulfite, the purpose of the present invention is to provide a tobramycin and ambroxol nebulized inhalation solution and a preparation method thereof that do not contain sodium bisulfite but have good product stability and therapeutic effects. Since ambroxol hydrochloride has a low solubility at room temperature, in order to shorten the process time, it is generally dissolved by heating, which not only increases the energy consumption of industrial production but also affects the stability of tobramycin that is sensitive to temperature. The present invention obtains an ambroxol hydrochloride solution by mixing ambroxol hydrochloride with a latent solvent and part of the injection water at room temperature, which can shorten the dissolution time of ambroxol hydrochloride and reduce the generation of impurities, and also reduce the energy consumption in the amplified production process, thereby improving production efficiency. And by selecting a specific thickener at the same time, the chemical stability of the tobramycin and ambroxol nebulized inhalation solution can be significantly improved by controlling the viscosity of the preparation, and it is also ensured that the preparation of the present invention has a good nebulized inhalation performance.
[0008] The tobramycin and ambroxol aerosol inhalation solution of the present invention is realized by the following technical scheme:
[0009] A tobramycin and ambroxol nebulized inhalation solution, the nebulized inhalation solution comprises the following components: tobramycin, ambroxol hydrochloride, a latent solvent, a thickener, an osmotic pressure regulator, a metal ion complexing agent, water for injection and a pH regulator, and the preparation process thereof comprises the following steps:
[0010] (1) Preparation of ambroxol hydrochloride solution: after mixing the latent solvent with water for injection to obtain a mixed solvent, add ambroxol hydrochloride and stir at room temperature until dissolved to obtain the ambroxol hydrochloride solution;
[0011] (2) Preparation of tobramycin solution: dissolving tobramycin, thickener, osmotic pressure regulator and metal ion complexing agent in water for injection to obtain tobramycin solution;
[0012] (3) Mix the ambroxol hydrochloride solution and the tobramycin solution, add water for injection, adjust the pH to 5.0-6.0 with a pH adjuster, filter and sterilize, and aseptically bottle into a single-dose packaging container.
[0013] Furthermore, the mass volume ratio of the latent solvent to the water for injection in the mixed solvent of step (1) is 1:50-150 g / mL.
[0014] Furthermore, the filtration sterilization in step (3) is performed using a 0.22 μm membrane filter.
[0015] In some embodiments, the single dose of the tobramycin and ambroxol nebulized inhalation solution provided by the present invention is 5 mL.
[0016] In some embodiments, the tobramycin and ambroxol nebulized inhalation solution provided by the present invention includes the following ingredients per 1000 mL: 30-90 g tobramycin, 1-6 g ambroxol hydrochloride, 1-3 g latent solvent, 5-15 g osmotic pressure regulator, 0.01-0.2 g metal ion complexing agent, water for injection, thickener and pH regulator, and its pH value is 5.0-6.0 and viscosity is 7.67-17.87 cp.
[0017] In some embodiments, the co-solvent comprises glycerol.
[0018] In some embodiments, the thickener is a water-soluble thickener, including one or more of sodium hyaluronate, sodium alginate, carbomer, polyethylene glycol, and polyvinyl alcohol, preferably hyaluronic acid or sodium alginate.
[0019] In some embodiments, the osmotic pressure regulator includes one or more of mannitol, glucose, sodium chloride, magnesium chloride and calcium chloride, preferably sodium chloride.
[0020] In some embodiments, the metal ion complexing agent includes one or more of disodium ethylenediaminetetraacetate, sodium ethylenediaminetetraacetate, calcium ethylenediaminetetraacetate, potassium ethylenediaminetetraacetate and ethylenediaminetetraacetic acid, preferably disodium ethylenediaminetetraacetate (EDTA-2Na).
[0021] In some embodiments, the pH adjuster includes one or more of hydrochloric acid, sulfuric acid, citric acid, disodium hydrogen phosphate-sodium dihydrogen phosphate buffer pair, acetic acid-sodium acetate buffer pair, citric acid-sodium citrate buffer pair and phosphoric acid-sodium phosphate buffer pair, preferably citric acid-sodium citrate buffer pair.
[0022] As a specific scheme, the tobramycin and ambroxol nebulized inhalation solution includes the following ingredients per 1000 mL: 30-90 g tobramycin, 1-6 g ambroxol hydrochloride, 1-3 g glycerol, 0.1-0.2 g sodium hyaluronate or sodium alginate, 5-15 g sodium chloride, 0.01-0.2 g disodium ethylenediaminetetraacetic acid, water for injection and an appropriate amount of citric acid-sodium citrate buffer, and its pH value is 5.0-6.0.
[0023] Specifically, the preparation process of the tobramycin and ambroxol nebulized inhalation solution comprises the following steps:
[0024] (1) Preparation of ambroxol hydrochloride solution: glycerol and water for injection are mixed to obtain a mixed solvent, and ambroxol hydrochloride is added thereto and stirred at room temperature until dissolved to obtain an ambroxol hydrochloride solution;
[0025] (2) Preparation of tobramycin solution: dissolving tobramycin, an optional thickener (sodium hyaluronate or sodium alginate), sodium chloride and disodium ethylenediaminetetraacetate in water for injection to obtain a tobramycin solution;
[0026] (3) Mix the ambroxol hydrochloride solution and the tobramycin solution, add water for injection, adjust the pH to 5.0-6.0 with citric acid-sodium citrate buffer, filter and sterilize, fill with nitrogen, and aseptically bottle into a single-dose packaging container.
[0027] The mass volume ratio of glycerol to water for injection in the mixed solvent of step (1) is 1:50-150 g / mL; a 0.22 μm membrane filter is used for filtering and sterilization in step (3), and the single dose of the sterile bottle is 5 mL.
[0028] As a preferred embodiment, the tobramycin and ambroxol nebulized inhalation solution includes the following ingredients per 1000 mL: 60 g tobramycin, 3 g ambroxol hydrochloride, 2 g glycerol, 0.2 g sodium hyaluronate, 8.5 g sodium chloride, 0.1 g disodium ethylenediaminetetraacetic acid, water for injection and an appropriate amount of citric acid-sodium citrate buffer, and its pH value is 5.5.
[0029] The method for preparing a tobramycin and ambroxol nebulized inhalation solution of the present invention has the following beneficial effects compared with the prior art due to the adoption of the above technical scheme:
[0030] 1. Tobramycin and ambroxol nebulized inhalation solution is prepared by dissolving ambroxol hydrochloride in a mixed solvent of a specific concentration and then mixing it with a tobramycin solution added with other pharmaceutical excipients. This not only shortens the dissolution time of ambroxol at room temperature, which is beneficial to improving the production efficiency in scale-up and process production, but also ensures the stability of tobramycin in the preparation process, and reduces the generation of impurities in ambroxol, thereby improving the safety of medication.
[0031] 2. The viscosity of the atomized inhalation solution is adjusted by using a latent solvent glycerol and a thickener, so that the drug stability in the compound atomized inhalation solution prepared by the present invention is increased, and at the same time, it is ensured that the atomization performance of the inhalation solution is not significantly different from that of the single-ingredient product on the market;
[0032] 3. Avoid using sodium bisulfite, an antioxidant that is irritating to the respiratory tract, and the quality of the prepared inhalation solution is stable, with no significant changes in properties, pH value, and total impurity content after 6 months of acceleration;
[0033] 4. The tobramycin and ambroxol nebulized inhalation solution prepared by the present invention provides a new administration method for patients with bronchiectasis accompanied by Pseudomonas aeruginosa infection, thereby improving the medication compliance of patients. DETAILED DESCRIPTION
[0035] The present invention is further described in detail in conjunction with the following specific examples, and the protection content of the present invention is not limited to the following examples. Without departing from the spirit and scope of the inventive concept, changes and advantages that can be thought of by those skilled in the art are included in the present invention, and the attached claims are the scope of protection. The process, conditions, reagents, experimental methods, etc. for implementing the present invention, except for the contents specifically mentioned below, are all common knowledge and common common sense in the art, and the present invention does not particularly limit the content.
[0036] Example 1-10 Preparation of Tobramycin and Ambroxol Nebulized Inhalation Solution
[0037] Table 1 Prescription table of Examples 1-10
[0038]
[0039] The preparation process includes the following steps:
[0040] (1) Preparation of ambroxol hydrochloride solution: glycerol is mixed with a portion of water for injection in the prescription to obtain a mixed solvent, and ambroxol hydrochloride is added and stirred at room temperature until dissolved to obtain an ambroxol hydrochloride solution;
[0041] (2) Preparation of tobramycin solution: dissolve tobramycin, an optional thickener (sodium hyaluronate or sodium alginate), sodium chloride and disodium ethylenediaminetetraacetate in an appropriate amount of water for injection to obtain a tobramycin solution;
[0042] (3) Mix the ambroxol hydrochloride solution and the tobramycin solution, add water for injection to 1000 mL, adjust the pH to 5.0-6.0 with citric acid-sodium citrate buffer, filter and sterilize with a 0.22 μm membrane filter, fill with nitrogen, and aseptically bottle into a single-dose packaging container of 5 mL.
[0043] Comparative Example 1 Preparation of Tobramycin and Ambroxol Nebulized Inhalation Solution
[0044] The recipe is the same as that of Example 8, except that the preparation process comprises the following steps:
[0045] Weigh the prescribed amount of tobramycin and dissolve it in an appropriate amount of water for injection, then add sodium chloride, EDTA-2Na and glycerol, mix well, add ambroxol hydrochloride and stir to dissolve at room temperature, make up the amount of water for injection to 1000 mL, adjust the pH to 5.5 with pH citric acid-sodium citrate buffer, filter and sterilize with a 0.22 μm membrane filter, fill with nitrogen, and aseptically bottle into a single-dose packaging container of 5 mL.
[0046] Comparative Example 2 Preparation of Tobramycin and Ambroxol Nebulized Inhalation Solution
[0047] The difference from Example 8 is that the prescription does not contain glycerin and the order of adding the thickener (sodium hyaluronate) in the preparation process is different. The preparation process includes the following steps:
[0048] (1) Preparation of ambroxol hydrochloride solution: dissolving sodium hyaluronate in a portion of the water for injection in the prescription to obtain a mixed solvent, adding ambroxol hydrochloride and stirring at room temperature until dissolved to obtain an ambroxol hydrochloride solution;
[0049] (2) Preparation of tobramycin solution: dissolve tobramycin, sodium chloride and disodium ethylenediaminetetraacetate in an appropriate amount of water for injection to obtain a tobramycin solution;
[0050] (3) Mix the ambroxol hydrochloride solution and the tobramycin solution, add water for injection to 1000 mL, adjust the pH to 5.5 with citric acid-sodium citrate buffer, filter and sterilize with a 0.22 μm membrane filter, fill with nitrogen, and aseptically bottle into a single-dose packaging container of 5 mL.
[0051] Comparative Example 3
[0052] The commercially available product purchased: Ambroxol hydrochloride solution for inhalation with the trade name of Yianping (specification: 2mL: 15mg).
[0053] Comparative Example 4
[0054] The commercially available product purchased: Tobramycin inhalation solution (specification: 5 mL: 300 mg) produced by Kangyuan Pharmaceutical Group Co., Ltd.
[0055] Test Example 1 Determination of dissolution time and viscosity of ambroxol hydrochloride
[0056] The dissolution time of ambroxol hydrochloride during the preparation of the ambroxol hydrochloride solutions of Comparative Examples 1-2 and Examples 1-10 was recorded, and the viscosity of the prepared tobramycin and ambroxol nebulized inhalation solutions was measured at 20° C. according to the viscosity determination method of Chinese Pharmacopoeia 0633, 2020 edition.
[0057] Table 2 Test results
[0058] Test items Dissolution time of ambroxol hydrochloride (min) Solution viscosity (cp) Comparative Example 1 30 17.75 Comparative Example 2 40 17.32 Example 1 7 1.01 Example 2 5 1.02 Example 3 4 1.04 Example 4 6 1.02 Example 5 6.5 1.02 Example 6 15 1.02 Example 7 5 7.67 Example 8 5 17.87 Example 9 5 31.34 Example 10 5 17.29
[0059] From the data of Comparative Example 1 and Examples 1-6, compared with tobramycin and ambroxol being dissolved in the same solution, dissolving ambroxol hydrochloride in a mixed solvent of a latent solvent and part of the water for injection and then mixing it with the tobramycin solution can shorten the dissolution time of ambroxol hydrochloride, which is conducive to the scale-up and industrial preparation of compound tobramycin and ambroxol atomized inhalation solution. By comparing Examples 1-6, it can be seen that when preparing the ambroxol hydrochloride solution, when the mass volume ratio of the latent solvent to the water for injection in the mixed solvent of step (1) is 1:50-150 g / mL, the ambroxol hydrochloride can be quickly dissolved, and as the amount of water for injection increases, the dissolution time of the ambroxol hydrochloride becomes longer.
[0060] Test Example 2 Stability Test
[0061] The formulation products of Comparative Examples 1-2 and Examples 1-10 were subjected to accelerated tests at a temperature of 25°C±2°C for 1 month, 3 months and 6 months respectively.
[0062] Chromatographic conditions: octadecylsilane bonded silica gel as filler, 0.01 mol / L diammonium hydrogen phosphate solution (pH adjusted to 7.0 with phosphoric acid)-acetonitrile (60:40) as flowability; column temperature: 40°C; flow rate: 1.0 mL / min; wavelength: 248 nm; injection volume: 20 μL;
[0063] Table 3 Stability test results
[0064]
[0065] Compared to Comparative Example 2, the tobramycin and ambroxol hydrochloride solutions of Examples 1-6 have relatively stable impurity content of ambroxol, proving that the addition of glycerol can reduce the generation of impurities. As can be seen from the comparison of Examples 7-10 with Examples 1-6, the addition of thickener sodium hyaluronate or sodium alginate can improve the chemical stability of tobramycin and ambroxol atomized inhalation solution, and significantly reduce the impurity content of ambroxol hydrochloride. And under the same prescription, the stability of the compound inhalation solution obtained by the preparation method of Example 8 is slightly better than the preparation method of conventional Comparative Example 1.
[0066] Test Example 3 Aerodynamic Characteristics Test
[0067] The aerodynamic properties of the samples of Comparative Examples 3-4 and Examples 7-10 were determined according to the method for determining the aerodynamic properties of fine particles of inhalation preparations in the Chinese Pharmacopoeia (General Rule 0951). The equipment was a pari nebulizer and a new generation impactor (NGI). The measurement indicators were delivery rate, fine particle dose (FPD), fine particle fraction (FPF) and aerodynamic mass median diameter (MMAD). The gas flow rate was 15 L / min, and the results were measured by high performance liquid chromatography (HPLC).
[0068] Table 4 Aerodynamic parameters tested in Comparative Examples 3-4 and Examples 7-10
[0069]
[0070] From the data of Examples 7-8 and 10, it can be seen that the tobramycin and ambroxol aerosol inhalation solutions prepared by the scheme of the present invention have no significant difference compared with Comparative Examples 3 and 4 (commercially available ambroxol hydrochloride solution for inhalation and tobramycin inhalation solution), indicating that the compound preparation prepared by the present invention has good atomization performance. However, in Example 9, due to the increase in viscosity, the delivery rate and FPD of ambroxol hydrochloride and tobramycin are reduced, and the atomized particle size increases. Therefore, it is also necessary to control the amount of thickener and control the sample viscosity of 7.67 to 17.87cp to ensure that the compound preparation has good atomization performance.
[0071] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. It should be pointed out that a person skilled in the art can make several improvements and modifications without departing from the technical principles of the present invention, and these improvements and modifications should also be regarded as within the scope of protection of the present invention.
Claims
1. A tobramycin and ambroxol nebulized inhalation solution, characterized in that: The atomized inhalation solution comprises the following ingredients: tobramycin, ambroxol hydrochloride, a latent solvent, a thickener, an osmotic pressure regulator, a metal ion complexing agent, water for injection, and a pH regulator. The preparation process comprises the following steps: (1) Preparation of ambroxol hydrochloride solution: After mixing the latent solvent with water for injection to obtain a mixed solvent, add ambroxol hydrochloride and stir at room temperature until dissolved to obtain the ambroxol hydrochloride solution; (2) Preparation of tobramycin solution: dissolve tobramycin, thickener, osmotic pressure regulator and metal ion chelating agent in water for injection to obtain tobramycin solution; (3) Mix the ambroxol hydrochloride solution and the tobramycin solution, add water for injection, adjust the pH to 5.0-6.0 with a pH adjuster, filter and sterilize, and aseptically bottle into a single-dose packaging container.
2. The tobramycin and ambroxol nebulized inhalation solution according to claim 1, characterized in that The mass volume ratio of the latent solvent to the water for injection in the mixed solvent of step (1) is 1:50-150 g / mL.
3. The tobramycin and ambroxol nebulized inhalation solution according to claim 1, characterized in that The filtration sterilization in step (3) is performed using a 0.22 μm membrane filter.
4. The tobramycin and ambroxol nebulized inhalation solution according to claim 1, characterized in that The co-solvent includes glycerol.
5. The tobramycin and ambroxol nebulized inhalation solution according to claim 1, characterized in that The thickener is a water-soluble thickener, including one or more of sodium hyaluronate, sodium alginate, carbomer, polyethylene glycol, and polyvinyl alcohol.
6. The tobramycin and ambroxol nebulized inhalation solution according to claim 1, characterized in that The osmotic pressure regulator includes one or more of mannitol, glucose, sodium chloride, magnesium chloride and calcium chloride; the metal ion complexing agent includes one or more of disodium edetate, sodium edetate, calcium edetate, potassium edetate and edetate; the pH regulator includes one or more of hydrochloric acid, sulfuric acid, citric acid, disodium hydrogen phosphate-sodium dihydrogen phosphate buffer pair, acetic acid-sodium acetate buffer pair, citric acid-sodium citrate buffer pair and phosphate-sodium phosphate buffer pair.
7. The tobramycin and ambroxol nebulized inhalation solution according to any one of claims 1 to 6, characterized in that The tobramycin and ambroxol nebulized inhalation solution comprises the following ingredients per 1000 mL: 30-90 g tobramycin, 1-6 g ambroxol hydrochloride, 1-3 g latent solvent, 5-15 g osmotic pressure regulator, 0.01-0.2 g metal ion complexing agent, water for injection, thickener and pH regulator. The pH value is 5.0-6.0 and the viscosity is 7.67-17.87 cp.
8. The tobramycin and ambroxol nebulized inhalation solution according to claim 7, characterized in that: The tobramycin and ambroxol nebulized inhalation solution comprises the following ingredients per 1000 mL: 30-90 g tobramycin, 1-6 g ambroxol hydrochloride, 1-3 g glycerol, 0.1-0.2 g sodium hyaluronate or sodium alginate, 5-15 g sodium chloride, 0.01-0.2 g disodium edetate, water for injection and an appropriate amount of citric acid-sodium citrate buffer solution, with a pH value of 5.0-6.
0.
9. The tobramycin and ambroxol nebulized inhalation solution according to claim 8, characterized in that The tobramycin and ambroxol nebulized inhalation solution includes the following ingredients per 1000 mL: 60 g tobramycin, 3 g ambroxol hydrochloride, 2 g glycerol, 0.2 g sodium hyaluronate, 8.5 g sodium chloride, 0.1 g disodium edetate, water for injection and an appropriate amount of citric acid-sodium citrate buffer solution, with a pH value of 5.5.
